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Abstract
Background: Microglial cells are the predominant immune cells in malignant brain tumors, but tumors may
release some factors to reduce their defensive functions. Restoration of the anti-cancer function of microglia has
been proposed as a treatment modality for glioblastoma. We examined the effect of intra-cranially administered
recombinant adeno-associated virus encoding interleukin-12 (rAAV2/IL12) on transfection efficiency, local immune
activity and survival in a rat model of glioblastoma multiforme.
Methods: F344 rats were injected with rAAV2/IL12 and implanted with syngeneic RG2 cells (glioblastoma cell line).
Intracerebral interleukin-12 and interferon-g concentrations were determined by ELISA. Activation of microglia was
determined by expressions of ED1 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) which were
evaluated by Western blotting and immunohistochemistry. The proliferation of cancer cells was evaluated with Ki67
immunohistochemistry and apoptosis of cancer cells with TUNEL.
Results: The brains treated with rAAV2/IL-12 maintained high expression of interleukin-12 and interferon-g for at
least two months. In syngeneic tumor model, brains treated with rAAV2/IL12 exhibited more infiltration of
activated microglia cells as examined by ED1 and TRAIL stains in the tumor. In addition, the volume of tumor was
markedly smaller in AAV2/IL12-treated group and the survival time was significantly longer in this group too.
Conclusion: The intra-cerebrally administered rAAV2/IL-12 efficiently induces long lasting expression of IL-12, the
greater infiltration of activated microglia cells in the tumor associated improved immune reactions, resulting in the
inhibited growth of implanted glioblastoma and the increased survival time of these rats.
Background
Interleukin-12 (IL-12) is a potent anti-cancer cytokine
that enhances innate and adaptive immune-responses.
At the molecular and cellular level, IL-12 facilitates
maturation of natural killer cells and cytotoxic T cells,
stimulates secretion of interferon-g (IFN-g) leading to
anti-angiogenesis, enhances secretion of the tumor
necrosis factor (TNF) superfamily leading to apoptosis,
and provokes antigen-specific adaptive immunity of
tumors via the TH1 pathway [1-4]. However, systemic
administration of recombinant IL-12 protein is asso-
ciated with a high risk of injury to vital organs [5,6].
Several preclinical studies, therefore, have attempted to
transfer IL-12 by direct injection into tumors or tumor
environments to reduce systemic toxicity [7,8].
Clinical trials have shown that gene transfer via an
adeno-associated virus (AAV) can be safe and effective.
In 1996, AAV-mediated gene transfer of the normal cys-
tic fibrosis transmembrane conductance regulator gene
was used to treat humans with cystic fibrosis [9], and
subsequent studies improve the therapeutic efficacy of
this treatment. In recent years, rAAV type 2 (rAAV2) has
been used to transfer the glutamic acid decarboxylase
gene into the subthalamic nucleus of patients with
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mediated transfer of the normal RPE65 gene into the
retina of patients with Leber’s congenital amaurosis pro-
moted expression of the transferred gene for at least one
year and patients experienced satisfactory therapeutic
responses [11].
Microglia cells play an important role in the develop-
ment of neoplasms in the central nervous system (CNS).
In healthy patients, microglial cells comprise 2-20% of
CNS cells and eliminate invading microbes or trans-
formed cells via major histocompatibility complex type 2
and/or phagocytosis [12,13]. However, in the presence of
a tumor, microglial cells infiltrate the tumor and can con-
stitute 10-34% of tumor cells and contribute to tumor
growth [14,15]. Tumors can secrete transforming growth
factor-b, matrix metaloproteases, and chemokines that
regulate the function of tumor-associated microglial cells,
and allow the tumor to continue to grow, develop, and
metastasize [16-18].
In this study, we developed a strategy for treatment of
gliobastoma multiforme in a rat model that employs intra-
cranial injection of rAAV2 that encodes IL-12. Our goal
was to extend the therapeutic window and reduce sys-
temic toxicity. The anti-cancer effects were evaluated by
measuring generation of IL-12, IFN-g, and tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL), and
induction of activated microglia cells.
Methods
Construction of rAAV2 encoding IL-12
The full length cDNA of rat IL-12 (InvivoGen, Sandiago,
USA) or enhanced green fluorescent protein (GFP, Invivo-
Gen, Sandiago, USA) was amplified using the polymerase
chain reaction (PCR) and subcloned into pAAV-MCS
(Stratagene, La Jolla, California, USA). The sequence was
verified by DNA sequencing (Protec, Oberstenfeld,
Germany). The procedures for creation of rAAV2 encod-
ing IL-12 (rAAV2/IL12) or GFP (rAAV2/GFP) include
5 main steps: transformation of E. coli, plasmid extraction,
culturing of HEK 293 cells, packaging of rAAV2/IL12 or
rAAV2/GFP in HEK 293 cells, and rAAV2/IL12 or
rAAV2/GFP purification [19]. In brief, E. coli (ECOS 101)
cells were used as competent cells, and were transformed
by pAAV-RC (Stratagene), pHelper (Stratagene), and
pAAV-IL-12 or rAAV2/GFP, then cultured at 37°C in
2YT-Broth A50 (Invitrogen, Carlsbad, USA) with ampicil-
lin (50 μg/mL). Transformed E. coli cells were resus-
pended in 2YT-Broth A50 and prepared for extraction of
the three plasmids. Plasmid DNAs were purified with a
plasmid Mega preparation kit (Qiagen, Duesseldorf,
Germany), and the extracted plasmids were quantified by
measuring the 260 nm/280 nm absorbance ratio. Frozen
HEK 293 cells were thawed at 37°C and cultured with
DMEM (Cellgro, Manassas, USA), 10% FBS (Hyclone,
Logan, USA), and 1% penicillin/streptomycin (Gibco,
Carlsbad, USA). The extracted plasmids, pAAV-RC,
pAAV-IL-12 (or pAAV2-GFP), and double the amount of
pHelper, were mixed and shaken with CaCl2. The mixture
was spread onto HEK 293 cell culture dishes and incu-
bated with DMEM, 10% FBS, and 1% P/S at 37°C for
rAAV/IL12 or rAAV2/GFP packaging. Finally, the pack-
aged rAAVs were purified on a heparin column (Heparin
Actigel Sterogen, San Gabriel, USA).
Animal model
The animal use protocol was reviewed and approved by
the Institutional Animal Care and Use Committee of
Tzu-Chi Hospital. F344 rats were purchased from the
NLAC (National Laboratory Animal Center, Taipei,
Taiwan) and bred in the Laboratory Animal Center of
Tzu-Chi University for acclimatization at least 7 days
before initiation of experiments. The F344 rat syn-
geneic GBM cell line RG2 was purchased from FIRDI
(Food Industry Research and Development Institute,
Hsinchu, Taiwan).
Injection of rAAV2/IL12 and implantation of RG2 cells
F344 rats (male, bodyweight, 200-250 g) were anesthetized
by intra-abdominal injection of diluted chloral hydrate
(40 mg/mL) at a dose of 1 mL/100 g bodyweight. The
head of the rat in prone position was fixed in the stereo-
tactic frame (Lab Standard™ Stereotaxic Instrument,
Wood Dale, USA). Craniostomy was performed under the
guidance of stereotactic frame with a target of 3 mm right
and 3 mm behind the bregma. A total of 30 μLr A A V 2 /
IL12 or rAAV2/GFP (1.96 × 10
12 particles/mL) was
injected 4 mm deep into the brain via a 50 μL syringe at a
rate of 5 μL/min. Ten minutes after completion of the
injection, the syringe was slowly withdrawn, the craniost-
omy was sealed with bone wax, and the wound was closed
with 3-0 nylon. Two weeks later, 500 RG2 cells in 10 μL
solution were injected into rat brain, under stereotactic
guidance, from the same burr hole, but 1 mm anterior to
virus injection site.
ELISA of IL-12 and IFN-g
After brains were harvested, 3 mm-thick slices were cut
using a rat brain-cutting apparatus. Total proteins were
separately extracted from brain sections of the right and
left hemispheres composed of maximal tumor volume
(Figure 2E). The concentrations of IL-12 and IFN-g were
determined with ELISA kits (R&D Systems, Minneapolis,
USA) according to the manufacturer’s instructions.
Briefly, the extracted lysates from brain sections were
incubated in 96-well microplates coated with anti-rat pri-
mary antibodies, then developed with secondary antibo-
dies conjugated with horseradish peroxidase. After
adding the substrate and stop solution, an Emax
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Valley, USA) was used to measure absorbance at 450 nm.
Western blotting of ED1 and TRAIL
A total of 20 μg protein was extracted from the brain slices
of the right and left hemispheres for Western blotting. The
activated microglia marker ED1 and TRAIL were checked.
After the procedure of SDS-PAGE, proteins were blotted
onto a PVDF membrane and then the membrane was
probed with monoclonal mouse anti-rat ED1 (mouse
monoclonal antibody to CD68, AbD Serotec, Kidlington,
UK) or polyclonal goat anti-rat TRAIL antibody (Santa
Cruz Biotechnology, USA) at a ratio of 1:100. The mem-
brane was further incubated with a secondary peroxidase-
labeled antibody and quantified by chemoluminescence.
Immunohistochemistry of TRAIL, activated microglia cells,
Ki67, and TUNEL
Brains were fixed in 4% formaldehyde and dehydrated.
The brain was cut into 3 mm thick slices with a rat brain-
cutting apparatus. The brain slices with maximal tumor
growth were further cut into 12 μm thick sections. These
brain sections, after rehydration and permeabilization with
a buffer solution, were then placed on slides and prepared
for staining.
For immumohistochemistry, these brain sections were
immersed in 3% hydrogen peroxide (to quench activity of
endogenous peroxidase) and then incubated with mono-
clonal mouse anti-rat ED1 (AbD Serotec), polyclonal goat
anti-rat TRAIL, Ki67 and TUNEL antibodies (Santa Cruz
Biotechnology). Antibodies were quantified with the
immunoperoxidase secondary detection system, according
to the manufacturer’s guidelines (Chemicon, Temecula,
USA).
Detection of nitric oxide (NO) after IL-12 stimulation in
vitro
2×1 0
5 BV2 cells (mouse microglia) were implanted and
cultured in each well of a 24 well plate. The cells were
treated with 5 different conditions which included blank
(negative control), 5 ng/ml IL-12, 10 ng/ml IL-12,
50 ng/ml IL-12, and LPS (positive control). After 24
hour incubation, 100 μl mixture of 1% Na solution and
1% Su solution were added in. After 10 minutes incuba-
tion, NO secretion was checked by detection of OD 500
(Molecular Devices, precision microplate reader).
Experimental protocol
A total of 106 rats were used in this study (Table 1).
They were divided into 6 groups.
Group 1 (n = 28):14 treated with AAV2/IL12 and 14
treated with AAV2/GFP. All rats were not implanted
with tumor. The level of IFN-g and IL-12 were detected
b yE L I S Ao nt h el a s td a yo fw e e k0 ,1 ,2 ,3 ,4 ,6 ,a n d8
(n = 2 each week) post treatment.
Group 2 (n = 18):9 treated with AAV2/IL12 and 9 trea-
ted with PBS. Following these treatments, all rats were
implanted with tumor (GBM). The level of IFN-g and IL-
12 were detected with ELISA on the last day of week 1, 2,
and 3 (n = 3 each week) post tumor implantation (i.e., on
the last day of week 3, 4, and 5 post viral or PBS).
Group 3 (n = 10):5 treated with AAV2/IL12 and
5 treated with PBS. Following these treatments, the rats
were further implanted with tumor. Western blot was
performed for TRAIL and ED1 on the last day of week
1 (n = 1, each group), 2 (n = 1, each group), and 3 (n =
3, each group) post tumor implantation. (Figure 3)
Group 4 (n = 8):4 treated with AAV2/IL12, 2 treated
with AAV2/GFP, and 2 treated with PBS. The treated
rats were further implanted with tumor. Immunohisto-
chemistry of brain sections of these rats was performed
for cell markers including TRAIL, ED1, Ki67 and
TUNEL on the last day of week 3 after tumor implanta-
tion. (Figures 4, 5, 6, 7 and 8)
Group 5 (n = 18):9 treated with AAV2/IL12 and 9
treated with PBS. Following these treatments, rats were
implanted with tumor. Tumor growth was estimated
from week 1 to week 3. (Figure 9)
Group 6 (n = 24):12 treated with AAV2/IL12 and 12
treated with PBS. Following these treatments, rats were
implanted with tumor. The survival days were recorded
for 8 weeks. (Figure 9)
Statistical analysis
All data are shown as mean ± standard deviation. Stu-
dent’s t-test was used to compare two groups and one-
way ANOVA with the Bonferroni post hoc correction
was used to compare multiple groups. The survival time
of the rat was analyzed by the Kaplan-Meier method
and the Log-rank test.
Results
Effect of rAAV2/IL12 on IFN-g and IL-12 expressions in the
brain without tumor implantation
For evaluating effectiveness of rAAV2/IL12 injection in
the brain in inducing an increased expression of IFN-g
and IL-12 in the brain, rats were treated with rAAV2/
IL12 (n = 14) or treated with AAV2/GFP (n = 14) but
not implanted with tumor. We evaluated time course of
IFN-g (Figure 1A) and IL-12 (Figure 1B) levels in both
groups.
Figure 1A shows that the mean levels of IFN-g in the
right hemisphere of the rAAV2/IL12 treated rats with
no tumor transplantation [rAAV/12 R (no) group] was
increased from 33.5 ± 2.2 pg/mg prior to the injection
to the maximum of 143.4 ± 15.5 pg/mg on the last day
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day of week-8; in the left hemisphere, the mean concen-
trations of IFN-g were increased from 31.2 ± 1.8 pg/mg
prior to injection to the maximum of 88.2 ± 1.8 pg/mg
on the last day of week-6, and declined to 40.0 ±
9.1 pg/mg on the last day of week-8. These findings
indicated an ipsilateral increase in concentrations of
IFN-g (Figure 1A) in AAV2/IL12 R(no) group. On the
other hand, the mean levels of IFN-g in both left and
right hemispheres of the rAAV2/GFP-treated rats with
no tumor implantation [AAV2/GFP L(no) and AAV2/
GFP R(no) groups] were all below 40 pg/mg, near the
pre-treated level, indicating that rAAV2/GFP did not
induce IFN-g immunoresponse.
Figure 1B shows that the mean concentrations of IL-12
in the right hemisphere of the rAAV2/IL12 treated rats
with no tumor implantation [AAV2/IL12 R(no) group]
were increased from 3.4 ± 2.1 pg/mg prior to the injection
to a maximum of 70.2 ± 12.3 pg/mg on the last day of
week 4, but declined to 34.2 ± 19.3 pg/mg on the last day
of week 8; the mean concentrations of IL-12 in the left
hemisphere of the same rats [AAV2/IL12 L(no) group]
were below 13 pg/mg at all time points. These findings
indicated an ipsilateral induction of IL-12 expression in
AAV2/IL12 R(no) group. The mean concentrations of IL-
12 in either left or right hemisphere of rAAV2/GFP-trea-
ted rats with no tumor implantation [AAV2/GFP L(no)
and AAV2/GFP R(no) groups] were all below 10 pg/mg
Table 1 Grouping of experiment
ELISA ELISA Western Blot Immunohistochemistry Tumor growth Survival
AAV2
/IL12
(no)#
AAV2
/GFP
(no)#
AAV2
/IL12
PBS AAV2
/IL12
PBS AAV2
/IL12
AAV2
/GFP
PBS AAV2
/IL12
PBS AAV2
/IL12
PBS
Week 0 2 2
Week 1 2 2 3 3 1 1 3 3
Week 2 2 2 3 3 1 1 3 3
Week 3 2 2 3 3 3 3 4 2 2 3 3
Week 4 2 2
Week 5
Week 6 2 2
Week 7
Week 8 2 2
Death 12 12
# (no) indicates no tumor implantation
Figure 1 Concentrations of IL-12 and IFN-g in right (R) and left (L) hemispheres of mice treated with rAAV2/GFP (n = 14) or rAAV2/IL-
12 (n = 14). All mice were not implanted with tumor as indicated by (no). We measured both IFN-g and IL-12 at the same time. IFN-g (A) and
IL-12 (B) levels, as expressed in picogram in 1 mg extracted protein, were measured by ELISA on the last day of week 0, 1, 2, 3, 4, 6, 8 (n = 2
each week) after injection of the virus vectors. All virus vectors were injected on the right hemisphere for this and the following experiments.
For the following experiments in tumor implantation, 500 cells of RG2 (GBM cell line) were injected into the brain 1 mm anterior to the vector
injection site on the last day of week 2 after the viral injection.
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did not induce IL-12 immunoresponse.
Tumor implantation alone slightly increased the level of
IFN-g, presumably by activation of preexisting immune
responses, and by infiltration into the contralateral hemi-
sphere. The increase in IL-12 mediated by rAAV2/IL12
had a restricted distribution, since it only occurred in the
hemisphere where the vector was injected.
Comparison of rAAV2/IL12 effects on IL-12 and IFN-g
expressions in the brain with or without tumor
implantation
We assessed the efficacy of our transfection system by
measuring IL-12 in the right and left brain hemispheres of
PBS-treated (n = 9) and rAAV2/IL12-treated (n = 9) rats
on the last day of week 1, 2, and 3 after tumor implanta-
tion (Figure 2).
Effect on IL12
Figure 2A shows that mean concentrations of IL-12 in
the right hemisphere of the rAAV2/IL12 treated rats
(AAV2/IL12 RH group) were 53.9 ± 29.4 pg/mg, 83.8 ±
27.0 pg/mg, and 93.4 ± 18.1 pg/mg, while in the left
hemisphere (AAV2/IL12 LH group), they were less than
13 pg/mg at all time points; on the other hand in both
hemispheres of the PBS-treated rats (PBS RH and PBS
LH groups), the mean concentrations of IL-12 were less
than 16 pg/mg at all time points. In comparison among
these four groups, the concentrations of IL-12 in the
AAV2/IL12 RH group were significantly higher than
those of the other three groups (p < 0.001 by ANOVA).
Figure 2B compares the data from AAV2/IL12 RH group
with AAV2/IL12 R(no) group, or compares those from
AAV2/IL12 LH group with those from AAV/IL12 L(no)
group, demonstrating that the concentrations of IL-12
were similar in either comparison. These findings indi-
cated that our vector increased IL-12 expression and that
this response was due to the vector that carries IL-12,
and not a secondary response to tumor implantation.
Effect on IFN-g
In the right hemisphere of the rAAV2/IL12 (AAV2/IL12
RH) group, the mean concentrations of IFN-g were 87.7 ±
14.1 pg/mg, 118.7 ± 25.2 pg/mg, and 129.0 ± 21.6 pg/mg;
in the left hemisphere (AAV2/IL12 LH), they were 68 to
86 pg/mg at all time points; while in both hemispheres of
the PBS-treated (PBS LH and PBS RH) groups, they were
68 to 80 pg/mg at all time points (Figure 2C). In compari-
son among above four subgroups, the concentrations of
IFN-g in the AAV2/IL12 RH group were significantly
higher (p < 0.001 by ANOVA) than those of the other
three subgroups (Figure 2C). Figure 2D compares the data
from AAV2/IL RH group with those from AAV2/IL R(no)
group, or compares those from AAV2/IL LH group with
those from AAV/IL12 L(no) group, demonstrating that
the concentrations of IFN-g were similar in either
comparison (Figure 2D). These findings indicated that our
vector ipsilaterally increased IFN-g expression and that
this response was due to the vector that carries IL-12, and
not a secondary response to tumor implantation.
Effect of rAAV2/IL12 on ED1 and TRAIL expression in the
brain implanted with tumor
This study evaluated whether the treatment of rAAV2/
IL12 can enhance an infiltration of the activated micro-
glias by comparing expressions of ED1 and TRAIL in
the brains treated with PBS and rAAV2/IL12 by Wes-
tern blotting. We found that expressions of ED1 and
TRAIL were ipsilaterally abundant in the rAAV2/IL12-
treated rats (Figure 3B), but less in the PBS-treated rats
(Figure 3A); these expressions were most prominent on
the last day of Week 3 after tumor implantation. The
ratio of ED1/actin and TRAIL/actin were detected of
the last day of week 3 (n = 3, each group) (GS-800 Cali-
brated Densitometer, Biorad). The mean value of ED1/
actin was 2.11 ± 0.27 of IL12-treated group and 0.95 ±
0.63 of PBS-treated group (p < 0.05 by t-test). The
mean value of TRAIL/actin was 1.62 ± 0.63 of IL12-
treated group and 0.67 ± 0.23 of PBS-treated group (p<
0.001 by t-test). These results indicate that activation of
microglia and secretion of TRAIL are induced by the
treatment of rAAV2/IL12.
S i n c ee x p r e s s i o n so fE D 1a n dT R A I Li nt h er A A V 2 /
IL12 and PBS treated rats were most prominent on the
last day of Week 3 after tumor implantation, the follow-
ing immunohistochemical studies on ED1, TRAIL, Ki67
and TUNEL staining were performed at this time point.
Effects of rAAV2/IL12 treatment on
immunohistochemistry for cell markers
For assessing immune responses induced by treatment
of rAAV2/IL12, immunohistochemistry for cell markers
i n c l u d i n gE D 1 ,T R A I L ,K i 6 7a n dT U N E Lw e r ec o m -
pared among brains treated with AAV2/IL12 (n = 4),
AAV2/GFP (n = 2), PBS (n = 2), or treated with nothing
(n = 1). Except for the rat treated with nothing, all other
rats were transplanted with tumor on the last day of
Week 2 after each treatment. Immunohistochemical
staining was performed on the last day of week-3 fol-
lowing tumor implantation.
Effect on ED1 and TRAIL stainings
The infiltration of activated microglial cells was exam-
ined by immunohistochemical staining of ED1 and
TRAIL, the markers of the activated. microglial cells.
The infiltration of ED1- and TRAIL-positive cells was
prominent, increasing from week 1 to week 3 in the
rAAV2/IL12-treated rats, but it was sparse in the PBS-
treated rats. Figure 4 shows that brain sections har-
vested from brains treated with rAAV2/IL12 (A, B, C,
D) show small tumor size and prominent dark-brown
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tumor; those with rAAV2/GFP (E, F) and PBS (G, H),
show sparse dark brown ED1 positive cells infiltrating in
four quadrants of the tumor; while the brain section
treated with nothing (I) does not show dark-brown
stained cells. These findings indicate that in the rAAV2/
L12-treated rats, numerous activated microglial cells had
clearly infiltrated the peripheral zone into the tumor;
Figure 2 Concentrations of IL-12 and IFN-g in right (R) and left (L) hemispheres of rats treated with PBS or rAAV2/IL-12 and with tumor
implantation. Concentrations of IL-12 (A) and IFN-g (C) were measured on the last day of week 1, 2, and 3 post tumor implantation (i.e., on the last
day of week 3, 4, and 5 post viral injection). The concentrations of IL-12 (A) and IFN-g (C) with tumor transplantation were compared to those of IL-12
(B) and IFN-g (D) with no tumor implantation (no). Note that both concentrations with no tumor implantation were taken from the data in Figure 1.
Photographs of 2 mm thickness brain sections (E) show rAAV2/IL12-treated (left 3 columns) and PBS-treated (right 3 columns) brains harvested on the
last day of week 1 (W1), week 2 (W2), and week 3 (W3) post tumor implantation. Black arrows indicate the maximal tumor size and this site was taken
for analyzing the concentration of IL-12 and IFN-g. PBS LH (diamond): left hemisphere from the PBS-treated; PBS RH (triangle): right hemisphere from
the PBS-treated; AAV2/IL12 RH (round): right hemisphere from the rAAV2/IL12-treated; AAV2/IL12 LH (square): left hemisphere from the rAAV2/IL12-
treated; AAV2/IL12 R(no) (empty square): right hemisphere of rAAV2/IL12-treated brain without tumor implantation; AAV2/IL12 L(no) (empty round):
left hemisphere from the rAAV2/IL12-treated brain without tumor implantation. The scale bar indicates 4 mm.
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only a few microglial cells infiltrated the tumor.
Figure 5 shows that brain sections harvested from rats
treated with rAAV2/IL12 have prominent cells stained
with dark brown TRAIL stain (A, B); those treated with
PBS show sparse cells stained with dark brown TRAIL
stain (C, D); that treated with nothing does not have
cells show dark brown TRAIL stain (E). The pattern of
infiltration of TRAIL positive cells into the tumor and
its peripheral zone were essentially similar to that of the
ED1 positive cells as in Figure 3. However, the intensity
of the TRAIL stain was stronger in intercellular matrix.
Although TRAIL stain was evident in the PBS group,
the stain was much weaker (Figure 5C, D).
Furthermore, Figure 6 shows that in the rAAV2/IL12
rats, high power microscopy demonstrating that microglial
cells were pleomorphic, ranged from hypertrophic and
amoeboid to compound granular corpuscles, indicating
transformation of microglia into active and mobile cells.
However, most of the microglial cells in the PBS group
were small and round or irregular in shape, indicating they
were in the inactive form.
Effect on Ki67 stain
The activity of tumor proliferation was estimated by Ki67
stain. The cells with Ki67 stain were prominent in rAAV2/
GFP treated tumors (Figure 7A, B) and only sparse in
rAAV2/IL12 treated tumors (Figure 7C, D). In 10 high
power fields of above brain sections of two rAAV/GFP-
treated tumors, the mean Ki67 positive cells were 117 and
110, respectively; while in those of the two rAAV2/IL12-
treated tumors, they were 26.3 and 16.8. These results
indicate that cell proliferation in rAAV2/IL12 treated
tumor was strongly inhibited.
Effect on TUNEL stain
The apoptosis of tumor cells was evaluated by TUNEL
stain. The apoptotic cells were more rAAV2/IL12-treated
tumors (Figure 8C, D) than the two rAAV2/GFP-treated
tumors (Figure 8A, B). In 10 high power fields of above
brain sections of two rAAV/GFP-treated tumors, the
mean apoptotic cells were 16.2 and 33.4, respectively;
w h i l ei nt h o s eo ft h et w or A A V 2 / I L 1 2 - t r e a t e dt u m o r s ,
they were 90.2 and 80.8. These results indicate that
rAAV2/IL12 can induce more apoptosis of tumor cells.
Effects of NO secretion of BV2 cells and stimulated by
IL-12 in vitro
In the test of BV2 groups, the OD value was 0.046 ±
0.002 of blank, 0.045 ± 0.001 of 5 ng/ml IL-12 treated,
0.043 ± 0.002 of 10 ng/ml IL-12 treated, 0.044 ± 0.001
of 50 ng/ml IL-12 treated, and 0.254 ± 0.018 of LPS
treated. There is no significant difference between IL-12
treated groups and blank, but significant difference
between LPS treated and the others (p < 0.001 by
ANOVA). This result indicates that LPS could induce
BV2 cells to secrete NO, but IL-12 could not induce
BV2 cells to secrete NO even in high dosage.
Effect of rAAV2/IL12 treatment on tumor growth
Rats were treated with rAAV2/IL12 (n = 9) and with
PBS (n = 9). Following these treatments, they were
Figure 3 Western blotting of ED1 (Marker of activated microglia) and TRAIL (tumor necrosis factor-related apoptosis-inducing ligand).
Brains were treated with PBS or rAAV2/IL12 and then implanted with tumor on the last day of Week 2 post viral vector injection. The brains
were used for Western blotting analysis of the expression of ED1, 34 kDa, and TRAIL, 104 kDa, from microglial cells on the last day of week 1, 2,
and 3 following tumor implantation. The brain slices for Western blotting analysis are shown at the bottom. All brains were harvested on the last
day of week 1, week 2, and week 3 post tumor implantation. The scale bars indicate 2 mm in brain sections.
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PBS (G, H, n = 2), accompanied with tumor implantation; and that in the brain section treated with nothing (n = 1).
Immunohistochemistry of brain sections was performed for ED1 on the last day of week 3 after tumor implantation. The brain sections were
stained with hematoxylin for nuclei and ED1 for activated microglial cells. The 1
st column shows the brain sections pictured before
immunostaining; the 2
nd column shows the brain sections pictured after staining; the 3
rd to 6
th columns show pictures taken at four quadrants
(black squares in 2
nd column) of the tumor adjacent to the normal tissue in the right hemisphere. ED1-positive cells show dark brown. The scale
bars indicate 2 mm in 1
st and 2
nd columns and 100 μmi n3
rd-6
th columns.
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Page 8 of 15implanted with tumor (GBM). The tumor growth was
not identifiable by gross view on the last day of week-1
for both groups; on the last day of week-2 (tumors had
grown for 2 weeks), the rAAV2/IL12 group appeared to
have small tumor (Figure 9A-C), but the PBS group had
larger tumor growth (Figure 9D-F); on the last day of
week-3, tumor growth was evident in both groups (Figure
9G-I and 9J-L). Tumor mass however was significantly
greater and was able to invade into the contralateral
hemisphere in the PBS group; occasionally, hemorrhage
in the tumor was also noted (Figure 9J-L). Above data
were summarized in Figure 7M. In the rAAV2/IL12
group, the mean tumor volume was 11.8 ± 6.0 mm
3 and
76.9 ± 9.7 mm
3 on the last day of week-2 and week-3,
respectively; in the PBS group, mean tumor volume was
61.1 ± 13.7 mm
3 and 105.9 ± 9.6 mm
3 on the last day of
week-2 and week-3, respectively. These differences were
statistically significant, (p < 0.01 by t-test).
Effect of rAAV2/IL12 treatment on survival rate of
GBM-implanted rats
Rats were treated with AAV2/IL12 and with PBS (n =
12 each group). Following these treatments, rats were
implanted with tumor. The survival days were recorded.
The mean survival time was 27.2 ± 3.0 days for the
rAAV2/IL12 group and 21.6 ± 1.3 days for the PBS
group (Figure 9N). Kaplan-Meier analysis and the Log-
rank test indicated that these differences were significant
(p < 0.00001).
Discussion
Ipsilateral expressions of IFN-g and IL12 by rAAV/IL12
The present findings demonstrate an ipsilateral increase in
concentrations of IFN-g (Figure 1A) and IL-12 (Figure 1B)
in AAV2/IL12 R(no) group; other findings cannot demon-
strate the induction of expression of IFN-g (Figure 1A)
and IL12 (Figure 1B) in AAV2/GFP L(no) and AAV2/GFP
R(no) groups. Comparison among AAV2/IL12 RH,
AAV2/IL12 LH, PBS RH, and PBS LH groups (Figure 2A
and 2C), we demonstrate that the concentrations of IL-12
(Figure 2A) and IFN-g (Figure 2C) in the AAV2/IL12 RH
group were the highest and those of the other three
groups were maintained at the baseline level. In addition,
the concentrations of IL12 (Figure 2B) and IFN-g (Figure
2D) were similar in both AAV2/IL RH group and AAV2/
IL R(no) group. These findings together indicated that our
Figure 5 Immunohistochemistry of TRAIL stain in brains treated with AAV2/IL12 (A, B)o rP B S( C, D), accompanied with tumor
implantation; and that in the brain treated with nothing (E). Brain sections used in Figure 4 were also stained with hematoxylin for nuclei
and TRAIL, and pictured as in Figure 4. TRAIL-positive cells show dark brown. The scale bars indicate 2 mm in 1
st and 2
nd columns and 100 μm
in 3
rd and 6
th columns.
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Page 9 of 15vector ipsilaterally increased both IL-12 and IFN-g expres-
sions and that this response was due to the vector that
carries IL-12, and not a secondary response to tumor
implantation.
Timing of expression of rAAV2-transfected genes
The timing of expression of vector-transferred genes in
the brain is important in the treatment of different CNS
diseases. The duration of transgene expression has not
been established for therapy of different cancers, but it is
expected to be shorter than that required for treatment
of neurodegenerative diseases. Several previous papers
have examined the expression of rAAV-transfected
genes. Warren and colleagues [20] injected rAAV2-lacZ
into the brains of BALB/c mice and found that b-gal
expression increased for the first two months, decreased
by month-4, and was not detectable in month-6 to
month-15. Sharon and colleagues [21]. injected rAAV2
and rAAV2-based serotypes rAAV2/1, rAAV2/5, and
rAAV2/8 encoding GFP into Sprague-Dawley rat brains.
Figure 6 Immunohistochemical stains of ED1 and TRAIL in brain sections treated with AAV2/IL12 (A, B)o rP B S( C, D), accompanied
with tumor implantation; and that in the brain treated with nothing (E). Brain sections used in Figure 4 were also stained with
hematoxylin for nuclei, ED1, and TRAIL, and pictured as in Figure 4. The 1
st and 2
nd columns show the low and high power fields of ED1 stain,
respectively; the 3
rd and 4
th columns show the low and high power fields of TRAIL stain. Cells stained with ED1 or TRAIL show dark brown. The
scale bars indicate 100 μm in low power field and 50 μm in high power field.
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Page 10 of 15GFP expression was detected after four days in all four
serotypes, reached a maximum in week-4, and was unde-
tectable in month-9. Injecting rAAV2/IL-12 into rat
brains without (Figure 1) or with (Figure 2) tumor
implantation in the present experiment, we found IL-12
and IFN-g were elevated from week-2 and peaked in
week-6. The sustained high levels of IL-12 and IFN-g
demonstrate that our methodology may be suitable for
cancer therapy.
Expressions of ED1 and TRAIL by rAAV2/IL transfection
TRAIL is secreted from several kinds of immune cells,
but secretion from microglia has only been recognized
in recent years. In particular, Sermin et al. found that
Figure 7 Immunohistochemistry of Ki67, a cell proliferation marker, in brains treated with rAAV2/GFP (A, B)o rr A A V 2 / I L 1 2( C, D),
accompanied with tumor implantation. On the last day of week-3 post tumor implantation, brain sections were harvested from two rAAV2/GFP-
treated rats (A, B) and two rAAV2/IL12-treated rats (C, D). Cells stained with Ki67 show dark brown. The scale bar indicates 100 μm (low power field).
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Page 11 of 15IFN-g and lipopolysaccharide upregulated TRAIL secre-
tion from a microglial cell line [22]. However, the intra-
cerebral concentration of IL-12 needed to induce
subsequent immune reactions mediated by the microglia
is not yet known.
We demonstrated that expressions of ED1 and TRAIL
were ipsilaterally abundant in the tumor tissue of
rAAV2/IL12-treated rats (Figure 3A), but less in that of
PBS-treated rats (Figure 3B), indicating that the rAAV2/
IL12 transfection can enhance more infiltration of
Figure 8 Immunohistochemistry of TUNEL, an apoptotic cell marker, in brains treated with rAAV2/GFP (A, B)o rr A A V 2 / I L 1 2( C, D),
accompanied with tumor implantation. On the last day of week-3 post tumor implantation, brain sections were harvested from two rAAV2/
GFP-treated rats (A, B) and two rAAV2/IL12-treated rats (C, D). Apoptotic cells stained with TUNEL show dark brown. The scale bar indicates 100
μm (low power field).
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Page 12 of 15Figure 9 Tumor growth and survival rate of rAAV2/IL12-treated and PBS-treated rats. Tumor growth was evaluated with brain slices
harvested on the last day of week-1 (n = 3 each group), week-2 (n = 3 each group), and week-3 (n = 3 each group) post tumor implantation.
The black arrows indicate the brain sections composed of maximal tumor mass, for delineation and estimation of tumor volume. The scale bar
indicates 2 mm. A-C. rAAV2/IL12-treated tumors grew for 2 weeks. D-F. PBS-treated tumors grew for 2 weeks. G-I. rAAV/IL12-treated tumors grew
for 3 weeks. J-L. PBS-treated tumors grew for 3 weeks. M. Mean tumor volume was estimated with Axiovision Rel. 4.7, Carl Zeiss Microimaging,
Stuttgart, Germany. N. The survival rate of rats was analyzed with Kaplan Meier method. The black line represents the survival curve of rAAV/IL12-
treated rats and the dot black line represents the survival curve of PBS-treated rats.
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Page 13 of 15activated microglias that secrete ED1 and TRAIL in the
transplanted tumor. These results were confirmed by
other studies using immunohistochemical stainings of
ED1-positive (Figures 4 and 6) and TRAIL-positive
(Figures 5 and 6) cells. These studies demonstrated that
the activated microglia stained with ED1 and TRAIL
abundantly infiltrated in the transplanted tumor trans-
fected with rAAV2/IL12.
Effects of rAAV2/IL12 transfection on Ki67 and TUNNEL
stains, tumor growth. And survival time
IL-12 and IFN-g are potent cytokines to enhance micro-
glial activity, and the activated microglias further express
IL-12 and IFN-g, resulting in a positive feedback-loop
[23-25]. Actively growing tumors can prevent activated
microglia from secretion of cytotoxic and apoptosis-asso-
ciated cytokines [15,26]. However, our use of rAAV2/IL12
that increased the intracerebral concentrations of IL-12
and IFN-g (Figures 1 and 2) and microglial infiltration
(Figures 3, 4, 5 and 6) modulated the tumor environment,
and restored the defensive function of the microglia. This
notion is evident in the findings in Figures 7, 8 and 9.
The activity of tumor proliferation was estimated by
Ki67 stain. The cells with Ki67 stain were prominent in
rAAV2/GFP treated tumors (Figure 7A, B) and only
sparse in rAAV2/IL12 treated tumors (Figure 7C, D),
demonstrating strongly significant difference between
rAAV2/IL12-treated and rAAV2/GFP-treated groups
(p < 0.00001). On the other hand, the apoptosis of tumor
cells was evaluated by TUNEL stain. The apoptotic cells
were more prominent in the rAAV2/IL12-treated tumors
(Figure 8C, D) than the rAAV2/GFP-treated tumors
(Figure 8A, B). These results indicated that in rAAV2/IL
treated tumor, cell proliferation was strongly inhibited,
while cell apoptosis markedly enhanced. In consistent
with these results, Figure 8 demonstrated that the tumor
volume was significantly smaller, while survival time
longer in the AAV2/IL12 transfected rats.
Clinical implications: Localized adjuvant therapy
In currently clinical practice, malignant brain tumors are
treated by surgical excision adjuvant with chemotherapy
and/or radiotherapy [27]. The BCNU wafer has been suc-
cessfully used as a local delivery agent for malignant brain
tumors; this delivery is associated with less systemic toxi-
city, prolonged therapeutic window, and reduced time
from surgical excision to drug administration [28,29]. The
BCNU wafer sustains a high therapeutic level of bis-chlor-
onitrosourea for only 2-3 weeks, not long enough to pre-
vent tumor relapse several months later. In our rat model,
however, intracerebral injection of rAAV2/IL-12 increased
IL-12 and IFN-g expressions for more than six weeks, sug-
gesting that this method can provide longer immune sur-
veillance. In addition, the resultant increase in activated
microglia was associated with minimal toxicity in the area
adjacent to the treated lesion, smaller tumor volume, and
longer survival time. Our results suggest that rAAV2 vec-
tors are feasible for somatic gene therapy of brain cancers.
Conclusions
Intracranial injection of rAAV2/IL12 increases expres-
sion of IL-12 and IFN-g in the brain implanted with
tumor. The increased immunoactivity can inhibit tumor
growth, and prolong survival time. Because rAAV2/IL12
requires few weeks of an incubation period and cannot
totally eliminate cancer cells, this treatment should be
considered as a possible adjuvant or concomitant ther-
apy for brain cancers when accompanied by surgery
and/or other treatment modalities.
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